Tscan Therapeutics Inc (TCRX) — Cash Flow-to-Debt Ratio
Tscan Therapeutics Inc (TCRX) has a Cash Flow-to-Debt Ratio of -0.23x as of March 2026, meaning its operating cash flow of $-24.28 Million could theoretically repay 0% of its total liabilities ($105.07 Million) in one year. See TCRX FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tscan Therapeutics Inc Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Tscan Therapeutics Inc across 7 annual periods. Also explore Tscan Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Tscan Therapeutics Inc (2019–2025)
Year-by-year debt coverage analysis for Tscan Therapeutics Inc. For market capitalisation and broader financial context, see market value of Tscan Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.28x | $-135.32 Million | $105.67 Million | ▼ -50.4% |
| 2024 | -0.85x | $-110.82 Million | $130.15 Million | ▼ -68.3% |
| 2023 | -0.51x | $-61.36 Million | $121.28 Million | ▲ +24.2% |
| 2022 | -0.67x | $-66.50 Million | $99.66 Million | ▲ +62.5% |
| 2021 | -1.78x | $-48.68 Million | $27.33 Million | ▼ -5332.4% |
| 2020 | -0.03x | $-3.02 Million | $92.20 Million | ▲ +98.2% |
| 2019 | -1.83x | $-12.52 Million | $6.84 Million | — |